Eisai Co., Ltd. (ESALF)
| Market Cap | 6.63B -17.1% |
| Revenue (ttm) | 5.19B +4.6% |
| Net Income | 242.50M -17.0% |
| EPS | 0.86 -16.5% |
| Shares Out | n/a |
| PE Ratio | 27.33 |
| Forward PE | n/a |
| Dividend | 1.04 (3.71%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 3,179 |
| Open | 23.88 |
| Previous Close | 28.00 |
| Day's Range | 23.88 - 23.88 |
| 52-Week Range | 23.88 - 35.83 |
| Beta | -0.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About Eisai
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in India. It also offers prescription medicines. In addition, the company focuses on neurology and oncology and therapeutic areas. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan. [Read more]
Financial Performance
In fiscal year 2026, Eisai's revenue was 825.38 billion, an increase of 4.56% compared to the previous year's 789.40 billion. Earnings were 38.56 billion, a decrease of -16.96%.
Financial numbers in JPY Financial StatementsNews
New Initiative by Eisai Expands Magnolia Meals at Home for Alzheimer's Care
New Initiative by Eisai Expands Magnolia Meals at Home for Alzheimer's Care
Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias
Expansion of Magnolia Meals at Home® offers brain-healthy guidance, recipes and resources for people living with ADRD and their care partners NUTLEY, N.J., June 1, 2026 /PRNewswire/ -- Eisai Inc. toda...
BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day
STOCKHOLM, May 25, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi. ...
Eisai Transcript: Investor Day 2026
The company outlined a three-year plan focused on making AD a curable disease, driving growth through LEQEMBI, LENVIMA, and DAYVIGO, and strengthening its neurology and oncology pipelines. FY2028 targets include JPY 1 trillion in revenue and JPY 90 billion in core operating profit, supported by new financial policies and cost reforms.
Eisai Slides: FY 2026
Eisai has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 25, 2026.
Full Year 2026 Eisai Co Ltd Earnings Presentation Transcript
Full Year 2026 Eisai Co Ltd Earnings Presentation Transcript
Eisai Earnings Call Transcript: Q4 2026
Revenue hit a record JPY 825.4B (+4.6% YoY), led by 3L products, but operating profit fell 18.8% due to fewer one-time gains and higher restructuring costs. FY 2026 targets record revenue and improved profitability, with LEQEMBI and BBM driving growth.
Eisai Quarterly report: Q4 2026
Eisai has published its Q4 2026 quarterly earnings report on May 15, 2026.
Eisai Slides: Q4 2026
Eisai has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 15, 2026.
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027)
STOCKHOLM, May 15, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 143.5 billion (approximately SEK 8.4...
FDA Extends Review of Eisai, Biogen Alzheimer's Drug
The agency pushed its decision on weekly subcutaneous LEQEMBI IQLIK for early Alzheimer's initial treatment to Aug. 24 after seeking additional information.
Eisai, Biogen Say FDA Extends Review Of LEQEMBI IQLIK As A Starting Dose For Early AD
(RTTNews) - Eisai Co. Ltd (ESALY.PK) and Biogen Inc. (BIIB) on Friday said the U.S. Food and Drug Administration has extended by three months the review of LEQEMBI IQLIK as a starting dose for the tre...
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage study
Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the main goals of a late-stage study, the companies said on Tuesday.
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease.
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer's Disease at the 78th American Academy of Neurology's Annual Meeting
NUTLEY, N.J., April 9, 2026 /PRNewswire/ -- Eisai Inc. announced today the company will present the latest findings on lecanemab (generic name, brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) pr...
Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
The Marketing Authorisation Application (MAA) has been validated and accepted for full approval consideration with a standard review timeline Additional filings are planned for the U.K., Canada and ot...
Eisai Earnings Call Transcript: Q3 2026
Q3 FY2025 saw 3.1% revenue growth to JPY 619.9B, driven by strong organic sales of LENVIMA, DAYVIGO, and LEQEMBI. Operating profit fell due to fewer one-time gains, but organic profit doubled. Oncology pipeline expanded with two in-licensing deals, and full-year guidance is maintained.
Eisai Quarterly report: Q3 2026
Eisai has published its Q3 2026 quarterly earnings report on February 9, 2026.
Eisai Slides: Q3 2026
Eisai has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 9, 2026.
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
TOKYO and SHANGHAI, Feb. 5, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO: Jason Zhu, "He...
Eisai strikes Japan licensing deal with Shanghai Henlius Biotech
Japan's Eisai will licence Shanghai Henlius Biotech's lung cancer drug Hansizhuang, paying $75 million upfront and up to $313.34 million more if milestones are met, the Chinese drugmaker said on Thurs...
Eisai Transcript: Status Update
The meeting highlighted a patient-centric, long-term strategy integrating social impact, innovation, and sustainability, with significant progress in dementia and oncology, enhanced R&D through AI, and targeted human capital initiatives. The Future Creation Strategy aims to ensure corporate value and societal contribution over 30 years.
Eisai Slides: Status Update
Eisai has posted slides in relation to its latest quarterly earnings report, which was published on December 9, 2025.
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
TOKYO and CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusett...
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in Phase I b /II study TOKYO , Dec. 1, 2025 /PRNewswire/ -- Eisai C...